OfferingRegistry
Offerings / Regulation CF / Cytonics Corp

Cytonics Corp

Regulation Crowdfunding offering on DealMaker Securities · Form C filed February 24, 2026 · Jupiter, Florida

Repeat issuerCommon stockEarly revenueCorporation, FloridaHealthcareBiotechnology research and development (osteoarthritis therapeutics and diagnostics)

Cytonics Corporation is a Florida research and development company developing protein-based therapies and diagnostics for osteoarthritis and back and joint pain, with its lead candidate CYT-108 in clinical development and licensing income from earlier products. The company was incorporated in 2006, reported revenue of $306,669 and a net loss of $4,526,921 for fiscal 2024, and is offering common stock with a $10,000 target and a $5,000,000 maximum.

Registry notesThe auditors have raised substantial doubt about the Company's ability to continue as a going concern, and the Company reported an accumulated deficit of $33,646,205 as of June 30, 2025. Investors must grant an irrevocable, indefinite proxy to the President to vote their shares, and the filing contains inconsistencies, including the incorporation date (July 19, 2006 in the summary versus July 26, 2006 in the business section) and Series A Preferred share counts that differ between sections.

Profile details below were extracted automatically from the issuer's filing documents. Figures in the financial table come directly from the SEC's structured Form C data.

Offering terms

Security
Common Stock
Maximum
$5,000,000.00
Price
$4.00 per unit
Pricing method
Not stated
Deadline
February 24, 2027
Oversubscriptions
Accepted
Intermediary
DEALMAKER SECURITIES LLC
Broker-dealer, SEC file 008-70756
Intermediary fee
The Company will pay DealMaker Securities LLC an 8.5% cash commission fee based on the dollar amount of the Securities sold in the Offering. There is also a one-time $13,750 fee and $12,000 monthly fee payable to DealMaker Securities and/or its affiliates.
Intermediary equity
None

Financials as filed

ItemMost recent FYPrior FY
Revenue$306,669$417,500
Cost of goods sold$0$0
Net income (loss)-$4,526,921-$1,946,860
Total assets$2,777,933$1,030,187
Cash and equivalents$2,432,955$602,933
Accounts receivable$50,000$196,191
Short-term debt$0$176,319
Long-term debt$0$0
Taxes paid$0$0

Two fiscal years as reported on the Form C cover sheet. 1 employees. Offered in 64 states.

Use of proceeds

At the $5,000,000 maximum: Intermediary fees $425,000; other offering expenses $249,000; clinical studies $2,000,000; drug production $1,000,000; working capital $1,326,000. If only the $10,000 target is raised, all proceeds go to Intermediary fees. The Company may alter the allocation.

Valuation

Fixed price of $4.00 per share set by the Board of Directors in its sole discretion, based on an internal valuation analysis comparing industry companies and the price of the Company's last capital raise, and on the projected value of the CYT-108 program. No independent valuation was obtained. Investors pay a 3.5% Investor Processing Fee, for an effective price of $4.14 per share.

Prior raises

Not stated

Financial statements

Financial statements are described as audited and are attached as Exhibit E. The auditor's name is not stated in the readable text. The risk factors state that the auditors expressed substantial doubt about the Company's ability to continue as a going concern.